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Abstract
A number of biological approaches to the management 
of inflammtory arthropathies have been explored.  These 
include the development of IL-1 receptor antagonists and TNF 
antagonists.  Four biological agents are currently marketed 
in Europe.  Most studies have revolved around Rheumatoid 
Arthritis, but an increasing number of studies are now completed 
or ongoing in the other inflammatory joint diseases.  These 
studies are reviewed in this article with a view to guiding practice 
and usage in the Maltese Islands.
Introduction
Rheumatoid arthritis (RA) is the most common chronic 
inflammatory arthritis in the UK with 0.5 – 1% of the population 
being affected.  RA accounts for significant morbidity and 
mortality and its medical costs in the UK account for nearly 8% 
of Health Service and related expenditure (Clinical management 
of RA and OA www.rheumatology.org.uk.  The overall annual 
inclusive cost of RA in the UK is between £0.8 and £1.3 billion 
with the majority of costs being generated by a small proportion 
of patients with severe disease.1
The aetiology of RA is unknown but it has a complex, 
multifactorial pathogenesis with a fluctuating clinical course and 
an unpredictable prognosis.  Approximately 15-30% of patients 
are unable to work within 1-2 years of onset of RA.
The goals of therapy are to relieve symptoms, including 
fatigue, pain, swelling and stiffness as well as the prevention of 
joint destruction, loss of joint function, deformity and disability. 
The gold standard is increasingly becoming the achievement 
of clinical remission although there is little evidence that 
conventional disease modifying agents even if started early or in 
combination can achieve this goal.  This has fuelled much of the 
research into new paradigms such as the biologic therapies.
The importance of anti-Tumour Necrosis Factor (anti-TNF) 
strategies in rheumatic diseases requires little introduction 
to rheumatologists.  Tumour Necrosis Factor (TNF) and 
Interleukin-1 (IL-1) are two of the most important cytokine 
mediators of the inflammatory response in a variety of 
conditions.  Produced primarily by activated macrophages, 
monocytes and endothelial cells, the effector functions of these 
two cytokines are similar and include a variety of powerful local 
and systemic effects.
Release of TNF leads to activation of vascular endothelium, 
including expression of adhesion molecules and upregulation 
of class II major histocompatibility (MHC) molecules.  These 
events orchestrate the recruitment of further inflammatory 
cells (neutophils, lymphocytes and monocytes) and increase 
production of immunoglobulins and complement proteins.  As 
a major cytokine in the inflammatory pathway, TNF stimulates 
the release of other pro-inflammatory cytokines, including 
interleukins (IL) -1, -6, and -8.
TNF and IL-1 also function synergistically to produce the 
rampant inflammatory cascade accompanying gram-negative 
sepsis, RA, and a variety of other inflammatory conditions.1
Three anti-TNF modalities are available for clinical use in 
the UK although only the first two have been formally appraised 
and approved by the National Institute of Clincal Excellence 
(NICE):
1. ETANERCEPT – a soluble 100% human peptide sequence 
made in vitro using recombinant DNA technology. 
Etanercept is a fusion protein made up of two recombinant 
p75 soluble receptors fused with the Fc fragment from the 
human IgG1.  It binds TNF-a and TNF-b.
2. INFLIXIMAB – A chimeric monoclonal IgG1 antibody with 
human (75%) constant and murine (25%) variable regions 
which bind soluble TNF-a in the plasma as well as cell 
membrane-bound TNF-a.
3. ADALIMUMAB – A recombinant fully humanised 
monoclonal antibody containing only human peptide 
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sequences.  It binds soluble TNF-a by blocking its 
interaction with p55 and p75 cell surface TNF receptors 
forming relatively large, stable trimer complexes that are 
rapidly and efficiently cleared from the body.2
One recombinant IL-1 Receptor antagonist (IL-1ra) is 
licensed: Anakinra.
Il-1ra is a naturally occurring competitive inhibitor of IL-1 
that shares approximately 40% sequence homology with IL-1. 
Il-1ra binds to the Il-1 receptor.  There are multiple isoforms 
of this enzyme, each released by activated macrophages, 
monocytes, neutrophils and hepatocytes.  Il-1ra isoforms 
function naturally as local anti-inflammatory mediators, and 
plasma levels are increased in patients with RA and Systemic 
Lupus Erythematosus. 3, 4
Recent animal model studies have examined the role of 
IL-1ra in vivo.5, 6  These studies show that low concentrations of 
IL-1ra are sufficient to control massive inflammatory responses. 
However, much higher concentrations of IL-1ra are required to 
suppress the IL-1 initiated inflammatory cascade completely. 
Exogenous IL-1ra molecules are therefore potentially very useful 
in systemic inflammatory disease such as RA and systemic 
vasculitis.
Contraindications / Precautions / Monitoring
TNF-alpha blockers are not recommended in women who 
are pregnant or breast-feeding.  They are contraindicated in 
active infection and in patients at high risk of infection, including 
chronic leg ulcers, tuberculosis, septic arthritis or continuing 
chronic sepsis of a prosthetic joint.  They are contraindicated 
in patients with a history of multiple sclerosis, in patients with 
malignancy or pre-malignancy excluding basal cell carcinoma 
and malignancies diagnosed and treated more than 10 years 
previously.  In patients with a past history of TB, it is prudent 
to give prophylactic treatment prior to commencing anti-TNF 
treatment.  Biologic agents are contraindicated in patients 
with moderate to severe heart failure but can be administered 
with caution to patients with mild heart failure (NYHA Class 
1-2).  Live vaccines should not be administered concurrently to 
patients receiving biologic therapies.
No particular blood monitoring is required.  However, 
all patients should be assessed to establish their response to 
treatment using objective response criteria such as the ones 
recommended by the BSR.  All patients have their details 
recorded in a central Biologics register.  Patients are followed up 




 Three placebo controlled Randomised Controlled Trials 
(RCT) have evaluated the use of infliximab in RA.7, 9  The first 
RCT (101 people) compared 1, 3, or 10 mg/kg infliximab with 
or without methotrexate (MTX) versus placebo.  It found a 
greater improvement with 3 or 10mg/kg infliximab versus 
placebo (ACR20 improvement: 60% in people taking 3 or 
10mg/kg infliximab vs 15% in people taking placebo).7  (See 
Table 1 for an explanation of ACR assessment criteria).
  The landmark ATTRACT study was a large multicentre 
RCT (428 people with active disease not responsive to MTX) 
comparing five groups over 12 months: placebo versus 
infliximab at 10mg/kg, given every 8 weeks.8  All continued 
to receive MTX.  AT 54 weeks ACR20 criteria were reached 
by 59% who received infliximab/MTX and by 20% of the 
MTX/placebo group.  ACR50 was attained by 39% of 
the people receiving infliximab and by 5% in the placebo 
group(P < 0.001; CI not provided).  Longer term results at 
54 weeks found that all infliximab groups improved versus 
placebo in terms of ACR20, ACR50, and ACR70 criteria (all 
results P<0.05; CI not provided).
  The important unblinded extension of the ATTRACT 
study was also recently reported.9  This lasted 102 weeks 
and 216 patients were studied.  The mean radiological 
progression was quite low (but not as low as with Etanercept) 
with the total Sharp score increasing by a mean of 1.14.  At 
102 weeks 48% of patients had achieved an ACR 20 and 
20% achieved an ACR 70.  No data was available regarding 
remission.
  In the RCTs, common adverse reactions were upper 
respiratory infections, headache, diarrhoea, and abdominal 
pain.  Reactions during or immediately after the injection 
(headache, nausea, urticaria) were also observed in the 
• Improvement in swollen joint count
• Improvement in tender joint count
• Improvement in at least three of the following measures:
 • Patient global assessment of disease activity
 • Physician global assessment of disease activity
 • Patient assessment of pain
 • Acute-phase reactant
 • Disability
The definition of response (ACR20, 50, 70) requires 
a 20%, 50% or 70% improvement in both tender and 
swollen joint count and a 20% improvement in three of 
the five remaining ACR core set measures.  Using these 
criteria, REMISSION is defined as:
• Morning stiffness absent or not exceeding 15 
minutes
• No fatigue
• No joint pain by history
• No joint tenderness
• No joint or tendon sheath swelling
• No elevation of ESR
Table 1: American College of Rheumtology 
 (ACR) Response Criteria.25
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placebo groups, but were more frequent with infliximab. 
Antibodies to double stranded DNA were found in about 
16% of people taking infliximab.
 The rates of serious adverse effects in both groups were not 
significantly different, but there was insufficient power to 
detect clinically important differences.  Worldwide, over 
150 cases of reactivation of TB have been documented, 
and people should be screened for previous TB before 
treatment.
2. Etanercept
 Two 6-month placebo controlled RCTs and two RCT that 
compared etanercept versus MTX have been published.10 
– 13  One RCT (234 people who had failed to respond to 
other disease modifying antirheumatic drugs) compared 
two doses of etanercept (10 and 25mg both given twice 
weekly) versus placebo.10  Improvement by at least 50% 
(ACR50 criteria) was found in 40% of people with high dose 
etanercept, in 24% with low dose etanercept, and in 5% with 
placebo (10mg vs placebo; P < 0.001; 25mg vs placebo; P 
< 0.001; 25mg vs 10mg; P = 0.032; CI not provided).  The 
RCT also found that etanercept improved functional status 
(measured by disability index; P , 0.05) and quality of life 
(measured by general health status; P < 0.05).
  The second RCT (89 people with inadequate response 
to MTX) compared etanercept (25 mg/wk) versus placebo.11 
People were allowed to continue MTX.  More people 
achieved ACR20 criteria with etanercept than with placebo 
(71% with etanercept vs 27% with placebo; P < 0.001; CI 
not provided).  A 12-month RCT (632 people with early 
rheumatoid arthritis) compared MTX versus two doses of 
etanercept (10 and 25mg both given twice weekly).12  It found 
significantly more people achieved ACR20, ACR50, and 
ACR70 responses with etanercept (25 mg) versus MTX at 6 
months.  By 12 months there was no significant difference in 
ACR response rate (72% with etanercept vs 65% with MTX; 
P = 0.16; CI not provided).  The higher dose etanercept was 
significantly better than the lower dose in terms of ACR20, 
ACR50, and ACR70 response at 12 months (P < 0.03 for all 
comparisons).
  The pivotal study for Etanercept is the TEMPO study.13 
This was a 52 week randomised, double-blind, clinical 
efficacy, safety and radiographic study in patients who 
were refractory to DMARDs other than methotrexate. 682 
patients were enrolled.  Three radiographic analyses were 
performed and in all cases there was a significant reduction 
in progression in the Etanercept + MTX arm (total Sharp 
score, change in erosions, change in joint space narrowing 
:- 0.54, -0.3, +0.23 respectively).  80% of patients showed 
no progression (radiological deterioration) at 12 months in 
the etanercept arm.  Markers of disease activity at 52 weeks 
(ACR20, ACR50, ACR70) were reached in 85%, 69% and 
43% respectively and 37% of patients were found to be in 
clinical remission.  One double blind RCT (424 people with 
rheumatoid arthritis for < 3 years) found no significant 
difference between entanercept (25mg sc twice weekly) 
versus oral MTX (rapidly escalating to 20 mg/wk) for health 
related quality of life at 52 weeks (SF-36 physical scale, mean 
improvement 10.7 points with etanercept vs 9.6 points with 
MTX, P = 0.84; SF-36 mental scale, mean improvement 3.6 
points with etanercept vs 4.1 points with MTX, P = 0.39; 
health related quality of life, mean improvement 0.73 points 
with etanercept vs 0.76 points with MTX, P = 0.46).14
  The common adverse effect was mild injection site 
reaction (42-49% in the treated group vs 7-13% in the 
placebo group).  One report of placebo-controlled trials 
(249 people on etanercept vs 152 people on placebo) 
found that injection site reactions were significantly more 
 ARMADA DE0 STAR DE0
Description Efficacy and saftey in  Radiographic progression Safety and efficacy Efficacy and saftey in
 MTX-resistant RA in  and physical function in RA with standard DMARD resistant RA
 patients with > 1 other  in MTX resistant RA rheumatologic care
 DMARD failure  (SOC
Treatments Humira + MTX vs. Huminra+ MTX vs. Humira + SOC vs. Humira monotherapy vs.
 Placebo + MTX Placebo + MTX  Placebo + SOC Placebo
Study Duration 24 weeks 52 weeks 24 weeks 26 weeks
Patients 271 619 636 544
RA duration 12.7 years 11 years 9.3 years 10.8 years
Mean HAQ 1.5 1.44 1.37 1.86
Mean CRP (mg/) 26 16 15 50
# failed DMARD 3 3 2.1 3.8
Table 2: Description of ADALIMUMAB pivotal trials and study populations 
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common for etanercept versus placebo.  (7.73 events/
patient years with etanercept vs 0.62 events/patient years 
with placebo, P < 0.001.15  Other adverse effects included 
upper respiratory symptoms or infections, headache, 
and diarrhoea.  Autoantibodies to double stranded DNA 
developed in 5-9% of the treated group.  Less than 1% of 
people developed malignancies or infections in the 6-month 
trials.  Reactivation of demyelinating disease has been 
described.  
3. Adalimumab
 As it is identical to full-length human immunoglobulin 
(IgG1), adalimumab shares the properties of a natural 
human IgG including a terminal half-life of about two weeks. 
In contrast, infliximab is cleared after about 8-9.5 days while 
etanercept is cleared after 70 hours.16
  The efficacy and safety of adalimumab is supported by 
evaluations in over 2400 patients with RA and more than 
5000 patient-years of exposure across 23 trials in Europe 
and the USA.  Four of these trials (Table 2) assessed the 
efficacy of adalimumab both as monotherapy as well as in 
combination with MTX.
4. Anakinra
 Approaches to the inhibition of IL-1 in RA have trailed 
the development of anti-TNF strategies.  Recombinant 
human IL-1ra has been studied both as monotherapy and 
in combination with disease-modifying agents in RA.  Daily 
subcutaneous injections resulted in up to 35% improvement 
in a number of clinical parameters, and patients receiving 
the highest doses of IL-1ra had radiographic improvement in 
bony erosions compared to placebo.17  Combination therapy 
of IL-1ra with MTX results in approximately 40% of patients 
receiving ACR 20 responses.18.
Juvenile Idiopathic Arthritis
There is currently no evidence to support treatment with 
biologic agents beyond 2 years and continuation of therapy is 
therefore dependent upon ongoing monitoring of disease activity 
and clinical effectiveness in the individual cases.  NICE appraised 
the evidence for etanercept in Juvenile Idiopathic Arthritis (JIA) 
in March 2002 and recommended its use for children aged 4 to 
17 years with active polyarticular JIA whose condition has not 
responded adequately to, or who have proved intolerant of MTX. 
NICE further recommends that initiation of etanercept therapy 
should only be undertaken by a consultant who regularly sees 
children with JIA.  In addition, the prescribing centre should 
have a nurse specialist or a trained nurse who is able to teach 
children and parents injection techniques.
Infection
The risk of serious and sometimes fatal infection is well 
documented during anti-TNF therapy.19-24   In a number of 
deaths administration of methylprednisolone in close temporal 
proximity to the initiation of anti-TNF therapy or the presence of 
severe organ compromise was postulated as a cause presumably 
due to increased (? excessive) immunosuppression.  However, 
all the fatalities occurred in patients above the age of 60 years 
so an age-related factor may also have been operative and may 
well be an independent risk factor for infection.20
The UK Position regarding TNF-Alpha 
blocking agents in Arthritis
Etanercept and Infliximab were reviewed under the NICE 
guidance of March 2002 regarding their use in RA and JIA. 
These agents have been recommended for use in patients who 
have continuing clinically active RA that has not responded to 
at least two disease-modifying anti-rheumatic drugs, including 
MTX (unless contraindicated).
TNF-alpha blocking agents are commenced under the 
direction of a consultant rheumatologist.  Effectiveness of the 
medications is assessed using the guidelines established by 
the British Society of Rheumatology which set out the criteria 
for eligibility, define response to treatment and define lack of 
response and criteria for cessation of therapy.  All clinicians 
prescribing TNF-a blocking agents should register the 
patient with the Biologics register established by the BSR and 
recommended by NICE.
Conclusions
TNF inhibitors  have provided a major advance in our 
therapeutic options for treating RA.  Understanding why some 
patients do not respond to these therapies remains a challenge 
and provides opportunities for a better understanding of the 
pathogenetic mechanisms operative in RA.  Important questions 
that remain regarding these therapies include the likelihood 
of opportunistic or unusual infections in the context of their 
chronic administration.
Finally, the costs of these potent therapies needs to be 
evaluated in terms of their long-term benefit, the predicted 
reduction in joint replacements, and their potential to provide 
improved quality of life.
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